Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

Gregory Q. Del Prete, Jeremy Smedley, Rhonda MacAllister, Gregg S. Jones, Bei Li, Jillian Hattersley, Jim Zheng, Michael Piatak, Brandon F. Keele, Joseph Hesselgesser, Romas Geleziunas, Jeffrey D. Lifson

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

The use of nonhuman primate (NHP) models to study persistent residual virus and viral eradication strategies in combination antiretroviral therapy (cART)-treated individuals requires regimens that effectively suppress SIV replication to clinically relevant levels in macaques. We developed and evaluated two novel cART regimens in SIVmac239-infected rhesus macaques: (1) a "triple regimen" containing the nucleo(s/t)ide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate [TDF, prodrug of tenofovir (TFV, PMPA)] with the integrase strand transfer inhibitor dolutegravir (DTG) (n = 3), or (2) a "quad regimen" containing the same three drugs plus the protease inhibitor darunavir (DRV) (n = 3), with each regimen coformulated for convenient administration by a single daily subcutaneous injection. Plasma drug concentrations were consistent across animals within the triple and quad regimen-treated groups, although DTG levels were lower in the quad regimen animals. Time to achieve plasma viral loads stably

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this